Precigen Inc, a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) is opening a new manufacturing facility, it was reported yesterday.

The company started construction of the facility in 2018 to support gene therapy manufacturing. It covers around 5,000 square foot area. The company says that the facility was designed with agility and control in mind, focusing on rapid manufacturing and the ability to scale production appropriately to meet early stage clinical trial needs. It adds to the company's present footprint in Germantown, Maryland, which supports more than 95 employees.

It includes ISO 7 cleanroom suites that will be utilised to manufacture gene therapy vectors, such as adenoviral vectors, including AdenoVerse vaccines and AdenoVerse cytokine therapies, and cell banks for early stage gene therapy trials. Due to the flexible design, other types of cell-based biopharmaceutical products can also be manufactured in the facility. Additionally, the facility includes a GMP quality control laboratory that supports lot release and stability testing.